Biotech Bid Up Following First Patient Dosage

By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, January 11, 2023

A Boston-based biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead ATR inhibitor for the treatment of cancers with DDR mutations, according to the release.

Traders quickly jumped at this opportunity and are currently bidding shares of Aprea Therapeutics Inc. (Nasdaq:APRE) up at $0.48/share (+5.40% implied open for sellers) at the time of writing. This move could be a strong continuation of the rally that has occurred since the company made a new 52-week low of $0.304 to finish the year of 2022.

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.